Lebrikizumab provided sustained itch relief and improved sleep quality through 52 weeks in individuals with ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from ...

Secondary outcomes were changes in PSSI, scalp surface area, Dermatology Life Quality Index (DLQI), Scalp Itch Numeric Rating Scale, Psoriasis Symptoms and Signs Diary, and complete clearance.

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted treatment approved for adults with this rare autoimmune blistering disease.

The researchers note that roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which targets inflammatory pathways central ...

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis ...

Achieved statistical significance for key secondary endpoints at week 16 of disease reduction, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA ...

This scale provided a measure of the broader impact of join pain and stiffness symptoms. Two single-item 7-point global rating of change scales for joint pain and stiffness were used to evaluate ...

Riyadh: Tassnief has assigned initial long-term entity rating of “AA+” (Double A Plus) to SNB Capital Company (‘SNBC’ or ‘the Company’) with a short-term rating of “T-1”. The outlook on the rating is ...

The purpose of this study was to empirically construct and demonstrate preliminary construct validity and interrater reliability of a pediatric sedation assessment scale, the State Behavioral ...